Abstract：
Information on microbial genome sequences is a powerful resource for accessing natural products with significant activities. We herein report the unveiling of lucensomycin production by Streptomyces achromogenes subsp. streptozoticus NBRC14001 based on the genome sequence of the strain. The genome sequence of strain NBRC14001 revealed the presence of a type I polyketide synthase gene cluster with similarities to a biosynthetic gene cluster for natamycin, which is a polyene macrolide antibiotic that exhibits antifungal activity. Therefore, we investigated whether strain NBRC14001 produces antifungal compound(s) and revealed that an extract from the strain inhibited the growth of Candida albicans. A HPLC analysis of a purified compound exhibiting antifungal activity against C. albicans showed that the compound differed from natamycin. Based on HR-ESI-MS spectrometry and a PubChem database search, the compound was predicted to be lucensomycin, which is a tetraene macrolide antibiotic, and this prediction was supported by the results of a MS/MS analysis. Furthermore, the type I polyketide synthase gene cluster in strain NBRC14001 corresponded well to lucesomycin biosynthetic gene cluster (lcm) in S. cyanogenus, which was very recently reported. Therefore, we concluded that the antifungal compound produced by strain NBRC14001 is lucensomycin.
摘要：
有关微生物基因组序列的信息是获取具有重要活性的天然产物的强大资源。我们在此报告了色链霉菌亚种生产萤光霉素的揭幕。链虫NBRC14001基于菌株的基因组序列。菌株NBRC14001的基因组序列揭示了I型聚酮合成酶基因簇的存在，与纳他霉素的生物合成基因簇相似，这是一种多烯大环内酯抗生素，具有抗真菌活性。因此,我们调查了菌株NBRC14001是否产生抗真菌化合物，并揭示了该菌株的提取物抑制了白色念珠菌的生长。对表现出针对白色念珠菌的抗真菌活性的纯化化合物的HPLC分析显示该化合物不同于纳他霉素。基于HR-ESI-MS光谱和PubChem数据库搜索，该化合物被预测为荧光霉素，这是一种四烯大环内酯抗生素，MS/MS分析的结果支持了这一预测。此外，菌株NBRC14001中的I型聚酮合成酶基因簇与氰化S.这是最近的报道。因此,我们得出结论，菌株NBRC14001产生的抗真菌化合物是lucensomycin。
